Drug administration and medical insurance bureau of Shaanxi Province should jointly inspect drugstores

▍ sorting out: Xi Yu < br / > from now on, the drugstore will check itself and eliminate these seven behaviorsFrom next month, the drug administration will carry out centralized inspection together with the medical insurance bureau< br / > on June 10, Shaanxi food and Drug Administration and medical insurance bureau jointly issued the notice on carrying out the special inspection on the centralized purchase and use of selected drugs organized by the state (hereinafter referred to as the "notice")< br / > < br / >< br / > from the date of the spontaneous document to the end of June 2020, the drug distribution enterprises, relevant medical institutions and drug retail enterprises involved in the selection of drugs shall conduct self inspection, carry out risk assessment, cause analysis, formulate rectification measures for the situation that may affect the quality of drugs and violate the relevant policies of medical insurance, and form a self inspection and rectification report, Respectively report to the provincial drug administration and relevant sub bureaus, provincial medical insurance bureau and municipal (District) medical insurance bureaus< br / > from July, for a period of three months, the provincial drug administration and its branches, provincial medical insurance bureau and municipal (District) medical insurance bureau organize the centralized inspection of the selected drugs in their respective jurisdictionsThe two departments shall, according to their responsibilities, supervise and urge the continuous compliance of the selected drug distribution enterprises, medical institutions and retail enterprises, so as to ensure the quality and safety of the selected drugs in the circulation and use process and meet the relevant requirements< br / > at the same time, the notice also makes clear that the key inspection varieties are the 32 varieties selected in the province from the national drug centralized procurement, and the selected drugs subsequently incorporated into the national drug centralized procurement and use< br / > for the retail enterprises involved in the selected drugs, the focus will be on the compliance inspection and drug quality managementAccording to the notice, we will mainly check the seven major behaviors of the enterpriseThe details are as follows: < br / > 1Whether there is the phenomenon of renting and lending license, affiliated to the ticket management; < br / > 2Whether there is the absence of licensed pharmacists, and the sales of prescription drugs are not standardized, The situation of selling prescription drugs or not keeping prescriptions without prescription; < br / > 3Whether there is the situation of purchasing or illegally recycling drugs from illegal channels; < br / > 4Whether there is a private warehouse outside the business place; < br / > 5Whether there is a drug shade cabinet or cold storage cabinet which is virtually empty, and does not open the cold storage cabinet or store the daily necessities; < br / > 6Whether there is a mixture of drugs and non drugs, The phenomenon of mixture of prescription drugs and over-the-counter drugs; < br / > 7 Whether the purchase and sale of the selected drugs in the retail drugstores conform to the relevant provisions of national health insurance < br / > in addition, according to the notice of the State Food and Drug Administration on carrying out the special inspection on the centralized purchase and use of selected drugs organized by the state (ZJJG [2020] No 18), this year, the special inspection on the centralized purchase and use of selected drugs will be carried out < br / > in the process of drug distribution and use, it is important to check the quality management of the selected drug distribution units and relevant medical institutions and retail enterprises Up to now, Jiangxi, Shanxi, Gansu, Ningxia, Hubei and other provinces have issued documents and started special inspection actions < br / > from the point of view of the time node, before June 30, 2020, all enterprises involved in the selection of drugs shall submit the self inspection report (with official seal) to the relevant regulatory authorities Starting in July, for a period of three months, the regulatory authorities will conduct a comprehensive centralized inspection < br / > original title: < br / >